← Leaderboards
France Carrier
University Of Maryland Baltimore
$2,949,818
Attributed
$4,766,850
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,554,726 · 6
VA$0 · 1
By mechanism
U19$7,787,876 · 1
R01$4,608,977 · 4
R41$157,873 · 1
I01$0 · 1
Top collaborators
- David Joseph Weber9 shared
- Steven Fletcher4 shared
- Isabel Lauren Jackson4 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- David Joseph Weber$22,294,951
- Huang Chiao Huang$6,185,360
- Matthew Ennis$4,961,995
- James E Polli$17,553,141
- Warren D D'souza$2,891,576
Others in their field
Top investigators on “Untranslated Regions”
- Manolis Kellis · Massachusetts Institute Of Technology$24,216,684
- Bing Ren · Ludwig Institute For Cancer Research$21,291,689
- Panagiotis Roussos · Icahn School Of Medicine At Mount Sinai$18,645,014
- Nenad Sestan · Yale University$18,340,124
- Michael P Snyder · Yale University$17,452,363
- Effie W Petersdorf · Fred Hutchinson Cancer Research Center$17,433,572
Research focus
Untranslated RegionsDna RepairDoseCellsApoptosisPharmaceutical PreparationsCancer TherapyProteinsCancer CellMolecularResponseProliferatingTumorToxic EffectXenograft ProcedureDown-RegulationTumor ProgressionXenograft ModelPreventNormal Tissue MorphologyDesignRegulatory PathwayCell PhysiologyAntineoplastic Agents
Grant awards (25)
First in Class Small molecules to simultaneously inhibit protein translation and an immune checkpoint in cancers$639,330
R01 · FY2025 · CA · contact PI
First in Class Small molecules to simultaneously inhibit protein translation and an immune checkpoint in cancers$184,185
R01 · FY2025 · CA · contact PI
Intercollaborative Radiation Countermeasure (INTERACT) Consortium for Advanced Development of Medical Countermeasures to Mitigate/Treat Acute and Delayed Radiation Syndromes$2,354,817
U19 · FY2024 · AI · contact PI
First in Class Small molecules to simultaneously inhibit protein translation and an immune checkpoint in cancers$639,330
R01 · FY2024 · CA · contact PI
Investigating the hnRNPA18-HIF-1a axis in solid tumors$75,447
R01 · FY2024 · CA · contact PI
Intercollaborative Radiation Countermeasure (INTERACT) Consortium for Advanced Development of Medical Countermeasures to Mitigate/Treat Acute and Delayed Radiation Syndromes$2,971,749
U19 · FY2023 · AI · contact PI
Preclinical Evaluation of Radioprotectin-1 for Mitigation of GI-ARS$23,254
U19 · FY2023 · AI · contact PI
Intercollaborative Radiation Countermeasure (INTERACT) Consortium for Advanced Development of Medical Countermeasures to Mitigate/Treat Acute and Delayed Radiation Syndromes$2,438,056
U19 · FY2022 · AI · contact PI
Chemopotentiation by Low Dose Fractionated Radiation Therapy for disseminated intra-abdominal cancers$0
I01 · FY2021 · VA · contact PI
Chemopotentiation by Low Dose Fractionated Radiation Therapy for disseminated intra-abdominal cancers$0
I01 · FY2020 · VA · contact PI
Chemopotentiation by Low Dose Fractionated Radiation Therapy for disseminated intra-abdominal cancers$0
I01 · FY2019 · VA · contact PI
Chemopotentiation by Low Dose Fractionated Radiation Therapy for disseminated intra-abdominal cancers$0
I01 · FY2018 · VA · contact PI
Rational targeting of protein translation of cancer treatments$318,513
R01 · FY2017 · CA · contact PI
Chemopotentiation by Low Dose Fractionated Radiation Therapy for disseminated intra-abdominal cancers$0
I01 · FY2017 · VA · contact PI
Rational targeting of protein translation of cancer treatments$318,513
R01 · FY2016 · CA · contact PI
Rational targeting of protein translation of cancer treatments$318,513
R01 · FY2015 · CA · contact PI
Rational targeting of protein translation of cancer treatments$308,957
R01 · FY2014 · CA · contact PI
Rational targeting of protein translation of cancer treatments$318,513
R01 · FY2013 · CA · contact PI
Biomodulation of anticancer drugs targeting DNA$228,000
R01 · FY2009 · CA · contact PI
Biomodulation of anticancer drugs targeting DNA$228,000
R01 · FY2008 · CA · contact PI
Biomodulation of anticancer drugs targeting DNA$228,000
R01 · FY2007 · CA · contact PI
RADIATION INDUCED RNA BINDING PROTEINS$275,451
R01 · FY2002 · GM
RADIATION INDUCED RNA BINDING PROTEINS$267,818
R01 · FY2001 · GM
Development of basic tools for Cancer Research$157,873
R41 · FY2001 · CA
RADIATION INDUCED RNA BINDING PROTEINS$260,407
R01 · FY2000 · GM